The company is using its proprietary Fast Evolution platform to develop arenavirus-based lead candidates with optimized anti-tumoral properties that can re-program the immune system to eliminate malignant tumor tissue. Abalos' virotherapy aims to activate all relevant immune cell types against primary tumors and metastases, providing a new approach to cancer treatment. With experienced biotech entrepreneurs and immunology pioneers leading the way, Abalos Therapeutics aims to achieve a quantum leap in immuno-oncology.